A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

NCT01419197 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

602

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab emtansine
DRUG: Treatment of physician's choice

Sponsor

Hoffmann-La Roche